Association between the Genomic Prostate Score and Metastatic Recurrence

The primary goal of the study is to confirm that the pre-specified Genomic Prostate Score (GPS) from biopsy tumor tissue predicts metastatic recurrence (MR) in patients diagnosed with localized prostate cancer and treated with radical prostatectomy. Prostate cancer-specific death (PCSD) will be evaluated as a secondary endpoint.

0